Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Pham

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
JCO Oncology Practice|July 24, 2024
Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive ChemotherapyYe Ji Lee, Thomas Delate, Rita L Hui, et al.
Global Advances in Integrative Medicine and Health|October 21, 2024
Implementation of Virtual, Livestream Yoga Classes for Veterans at Home During the COVID-19 Pandemic: A Mixed-Methods Pilot Program EvaluationCatherine Pham, Caitlin Hildebrand, Gary Tarasovsky, et al.
Clinical Rheumatology|November 22, 2023
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-attoCatherine Pham, Fang Niu, Rita L Hui, et al.
MCN. the American Journal of Maternal Child Nursing|August 13, 2025
Racial Minority Doulas' Perceptions of Hospital Team-Based CareLeanne T Burke, Elaha Noori, Catherine Pham, et al.
Expert Opinion on Biological Therapy|April 1, 2025
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-attoCatherine Pham, Deana Bitar, Fang Niu, et al.
Expert Opinion on Biological Therapy|October 10, 2025
Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritisAntony T-H Lin, Fang Niu, Rita L Hui, et al.
Journal for Immunotherapy of Cancer|November 14, 2025
Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survivalAlexander W Rankin, Catherine Pham-Danis, Amanda J Novak, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2023
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal CancerCatherine Pham, Fang Niu, Thomas Delate, et al.
JAMA Internal Medicine|October 3, 2022
Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016Beatrice L Brown, Mayookha Mitra-Majumdar, Jonathan J Darrow, et al.
Journal of Health Politics, Policy and Law|July 22, 2022
Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature ReviewBeatrice L Brown, Mayookha Mitra-Majumdar, Krysten Joyce, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
JCO Oncology Practice|July 24, 2024
Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive ChemotherapyYe Ji Lee, Thomas Delate, Rita L Hui, et al.
Global Advances in Integrative Medicine and Health|October 21, 2024
Implementation of Virtual, Livestream Yoga Classes for Veterans at Home During the COVID-19 Pandemic: A Mixed-Methods Pilot Program EvaluationCatherine Pham, Caitlin Hildebrand, Gary Tarasovsky, et al.
Clinical Rheumatology|November 22, 2023
Patient perceptions on switching from reference product adalimumab to biosimilar adalimumab-attoCatherine Pham, Fang Niu, Rita L Hui, et al.
MCN. the American Journal of Maternal Child Nursing|August 13, 2025
Racial Minority Doulas' Perceptions of Hospital Team-Based CareLeanne T Burke, Elaha Noori, Catherine Pham, et al.
Expert Opinion on Biological Therapy|April 1, 2025
Perceptions of patients with inflammatory bowel diseases on switching from reference product adalimumab to biosimilar adalimumab-attoCatherine Pham, Deana Bitar, Fang Niu, et al.
Expert Opinion on Biological Therapy|October 10, 2025
Clinical and out-of-pocket cost outcomes after switching to biosimilar adalimumab-atto in patients with rheumatoid arthritisAntony T-H Lin, Fang Niu, Rita L Hui, et al.
Journal for Immunotherapy of Cancer|November 14, 2025
Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survivalAlexander W Rankin, Catherine Pham-Danis, Amanda J Novak, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 25, 2023
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal CancerCatherine Pham, Fang Niu, Thomas Delate, et al.
JAMA Internal Medicine|October 3, 2022
Fulfillment of Postmarket Commitments and Requirements for New Drugs Approved by the FDA, 2013-2016Beatrice L Brown, Mayookha Mitra-Majumdar, Jonathan J Darrow, et al.
Journal of Health Politics, Policy and Law|July 22, 2022
Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature ReviewBeatrice L Brown, Mayookha Mitra-Majumdar, Krysten Joyce, et al.
Pageof 4